Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or m⦠read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
$2.66
Price+23.15%
$0.50
$88.290m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$67.808m
-
1y CAGR-
3y CAGR-
5y CAGR-$2.22
-
1y CAGR-
3y CAGR-
5y CAGR$15.949m
$21.116m
Assets$5.167m
Liabilities-
Debt0.00%
-
Debt to EBITDA-$49.925m
-
1y CAGR-
3y CAGR-
5y CAGR